ପେନସାଇକ୍ଲୋଭିର

ପେନସାଇକ୍ଲୋଭିର
Clinical data
Pronunciation	/ˌpɛnˈsaɪkloʊˌvɪər/
Trade names	Denavir, others
AHFS/Drugs.com	monograph
MedlinePlus	a697027
Pregnancy; category	AU: B1 ; US: B (No risk in non-human studies) ; ;
Routes of; administration	Topical
Legal status
Legal status	AU: S2 (Pharmacy only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	1.5% (oral), negligible (topical)
Protein binding	<20%
Metabolism	Viral thymidine kinase
Elimination half-life	2.2–2.3 hours
Excretion	Renal
Identifiers
	IUPAC name 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6(9H)-one;
ECHA InfoCard	100.189.687
Chemical and physical data
Formula	C10H15N5O3
Molar mass	୨୫୩.୨୬ g·mol−1
3D model (JSmol)	Interactive image;
Melting point	275 to 277 °C (527 to 531 °F)
	SMILES O=C2/N=C(\Nc1n(cnc12)CCC(CO)CO)N;
	InChI InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18) ; Key:JNTOCHDNEULJHD-UHFFFAOYSA-N ;
(verify)

ପେନସାଇକ୍ଲୋଭିର (ଇଂରାଜୀ ଭାଷାରେ Penciclovir), ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଡେନାଭିର ଏକ ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଓଠର ହର୍ପିସ ସଂକ୍ରମଣର (ଥଣ୍ଡା ଘା) ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୨] ଏହା ୮ରୁ ୭ ଦିନ ପର୍ଯ୍ୟନ୍ତ ଆରୋଗ୍ୟ ସମୟ ହ୍ରାସ କରେ ।^[୩] ଏହା ସଂକ୍ରମିତ ସ୍ଥାନରେ ପ୍ରୟୋଗ କରାଯାଏ ।^[୨]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଔଷଧ ପ୍ରୟୋଗ ସ୍ଥଳରେ ଉତ୍ତେଜନା ହୋଇପାରେ ।^[୨] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ସୁରକ୍ଷିତ ଥିବା ପରି ଜଣାଯାଏ ।^[୪] ଏହା ଏକ ନ୍ୟୁକ୍ଲିଓସାଇଡ ଆନାଲଗ ଓ ଆସାଇକ୍ଲୋଭିର ସଦୃଶ ଅଟେ ।^[୨] ଫ୍ୟାମିସାଇକ୍ଲୋଭିର ହେଉଛି ପେନସାକ୍ଲୋଭିରର ଏକ ପୂର୍ବବର୍ତ୍ତୀ (precursor) ଔଷଧ | ^[୫]

୧୯୯୬ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ପେନସାଇକ୍ଲୋଭିର ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୬] ^[୨] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ମସିହା ସୁଦ୍ଧା ୫ ଗ୍ରାମର ଟ୍ୟୁବ୍ କ୍ରିମର ମୂଲ୍ୟ ୮୦୦ ଡଲାର ଥିଲା ।^[୭] ଅନ୍ୟାନ୍ୟ ସମାନ ଉପଯୋଗୀ ଔଷଧ ଅପେକ୍ଷା ଏହା ମହଙ୍ଗା ଅଟେ ।^[୩]

ଆଧାର

↑ "Penciclovir". Merriam-Webster Dictionary.
↑ ^୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ "Penciclovir Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 17 April 2021. Retrieved 27 October 2021.
↑ ^୩.୦ ^୩.୧ "Penciclovir" (PDF). Archived (PDF) from the original on 15 April 2021. Retrieved 27 October 2021.
↑ "Penciclovir topical (Denavir) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 5 December 2020. Retrieved 27 October 2021.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 672. ISBN 978-0857114105.
↑ Long SS, Pickering LK, Prober CG (2012). Principles and Practice of Pediatric Infectious Disease (in ଇଂରାଜୀ). Elsevier Health Sciences. p. 1502. ISBN 978-1437727029. Archived from the original on 2019-12-29. Retrieved 2021-03-22.
↑ "Penciclovir Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 27 October 2021. Retrieved 27 October 2021.

[1] "Penciclovir". Merriam-Webster Dictionary.

[AHFS2021-2] ୨.୦ ^୨.୧ ^୨.୨ ^୨.୩ ^୨.୪ "Penciclovir Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 17 April 2021. Retrieved 27 October 2021.

[CED2018-3] ୩.୦ ^୩.୧ "Penciclovir" (PDF). Archived (PDF) from the original on 15 April 2021. Retrieved 27 October 2021.

[4] "Penciclovir topical (Denavir) Use During Pregnancy". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 5 December 2020. Retrieved 27 October 2021.

[BNF81-5] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 672. ISBN 978-0857114105.

[6] Long SS, Pickering LK, Prober CG (2012). Principles and Practice of Pediatric Infectious Disease (in ଇଂରାଜୀ). Elsevier Health Sciences. p. 1502. ISBN 978-1437727029. Archived from the original on 2019-12-29. Retrieved 2021-03-22.

[7] "Penciclovir Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 27 October 2021. Retrieved 27 October 2021.

[୨]

[୩]

[୧]

[୪]

[୫]

[୬]

[୭]

Clinical data

Pronunciation	/ˌpɛnˈsaɪkloʊˌvɪər/^[୧]
Trade names	Denavir, others
AHFS/Drugs.com	monograph
MedlinePlus	a697027
Pregnancy category	AU: B1 US: B (No risk in non-human studies)
Routes of administration	Topical
Legal status
Legal status	AU: S2 (Pharmacy only) US: ℞-only
Pharmacokinetic data
Bioavailability	1.5% (oral), negligible (topical)
Protein binding	<20%
Metabolism	Viral thymidine kinase
Elimination half-life	2.2–2.3 hours
Excretion	Renal
Identifiers
IUPAC name 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6(9H)-one
ECHA InfoCard	100.189.687
Chemical and physical data
Formula	C₁₀H₁₅N₅O₃
Molar mass	୨୫୩.୨୬ g·mol⁻¹
3D model (JSmol)	Interactive image
Melting point	275 to 277 °C (527 to 531 °F)
SMILES O=C2/N=C(\Nc1n(cnc12)CCC(CO)CO)N
InChI InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)^Y Key:JNTOCHDNEULJHD-UHFFFAOYSA-N^Y
(verify)